vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and PROG Holdings, Inc. (PRG). Click either name above to swap in a different company.
ALNYLAM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($1.2B vs $651.6M, roughly 1.8× PROG Holdings, Inc.). ALNYLAM PHARMACEUTICALS, INC. runs the higher net margin — 17.6% vs 5.5%, a 12.1% gap on every dollar of revenue. On growth, PROG Holdings, Inc. posted the faster year-over-year revenue change (457.1% vs 96.4%). Over the past eight quarters, ALNYLAM PHARMACEUTICALS, INC.'s revenue compounded faster (33.0% CAGR vs 4.9%).
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
PROG Holdings, Inc. is a U.S.-based financial technology firm providing flexible lease-to-own and point-of-sale financing solutions to consumers. Operating primarily in the U.S. market, its core segments include retail partner financing, consumer lending, and payment services that help customers access electronics and household goods without traditional credit requirements.
ALNY vs PRG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $651.6M |
| Net Profit | $206.0M | $36.1M |
| Gross Margin | 82.2% | — |
| Operating Margin | 23.0% | 10.0% |
| Net Margin | 17.6% | 5.5% |
| Revenue YoY | 96.4% | 457.1% |
| Net Profit YoY | — | 3.8% |
| EPS (diluted) | $1.51 | $3.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | $651.6M | ||
| Q4 25 | $1.1B | $525.4M | ||
| Q3 25 | $1.2B | $595.1M | ||
| Q2 25 | $773.7M | $604.7M | ||
| Q1 25 | $594.2M | $684.1M | ||
| Q4 24 | $593.2M | $558.9M | ||
| Q3 24 | $500.9M | $606.1M | ||
| Q2 24 | $659.8M | $592.2M |
| Q1 26 | $206.0M | $36.1M | ||
| Q4 25 | $186.4M | $40.5M | ||
| Q3 25 | $251.1M | $33.1M | ||
| Q2 25 | $-66.3M | $38.5M | ||
| Q1 25 | $-57.5M | $34.7M | ||
| Q4 24 | $-83.8M | $57.5M | ||
| Q3 24 | $-111.6M | $84.0M | ||
| Q2 24 | $-16.9M | $33.8M |
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — |
| Q1 26 | 23.0% | 10.0% | ||
| Q4 25 | 12.0% | 6.9% | ||
| Q3 25 | 29.5% | 9.0% | ||
| Q2 25 | -2.1% | 10.0% | ||
| Q1 25 | 3.0% | 8.2% | ||
| Q4 24 | -17.7% | 8.9% | ||
| Q3 24 | -15.4% | 8.1% | ||
| Q2 24 | 7.4% | 9.4% |
| Q1 26 | 17.6% | 5.5% | ||
| Q4 25 | 17.0% | 7.7% | ||
| Q3 25 | 20.1% | 5.6% | ||
| Q2 25 | -8.6% | 6.4% | ||
| Q1 25 | -9.7% | 5.1% | ||
| Q4 24 | -14.1% | 10.3% | ||
| Q3 24 | -22.3% | 13.9% | ||
| Q2 24 | -2.6% | 5.7% |
| Q1 26 | $1.51 | $3.68 | ||
| Q4 25 | $1.44 | $0.99 | ||
| Q3 25 | $1.84 | $0.82 | ||
| Q2 25 | $-0.51 | $0.95 | ||
| Q1 25 | $-0.44 | $0.83 | ||
| Q4 24 | $-0.66 | $1.33 | ||
| Q3 24 | $-0.87 | $1.94 | ||
| Q2 24 | $-0.13 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $69.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $774.4M |
| Total Assets | $5.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.7B | $69.4M | ||
| Q4 25 | $1.7B | $308.8M | ||
| Q3 25 | $1.5B | $292.6M | ||
| Q2 25 | $1.1B | $222.0M | ||
| Q1 25 | $1.0B | $213.3M | ||
| Q4 24 | $966.4M | $90.9M | ||
| Q3 24 | $1.1B | $221.7M | ||
| Q2 24 | $968.5M | $250.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $594.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $643.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.1B | $774.4M | ||
| Q4 25 | $789.2M | $746.4M | ||
| Q3 25 | $233.9M | $703.6M | ||
| Q2 25 | $250.6M | $668.7M | ||
| Q1 25 | $115.4M | $654.4M | ||
| Q4 24 | $67.1M | $650.3M | ||
| Q3 24 | $32.4M | $630.8M | ||
| Q2 24 | $-3.1M | $581.9M |
| Q1 26 | $5.1B | $2.0B | ||
| Q4 25 | $5.0B | $1.6B | ||
| Q3 25 | $4.9B | $1.5B | ||
| Q2 25 | $4.6B | $1.5B | ||
| Q1 25 | $4.2B | $1.5B | ||
| Q4 24 | $4.2B | $1.5B | ||
| Q3 24 | $4.2B | $1.4B | ||
| Q2 24 | $4.0B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
PRG
Segment breakdown not available.
